Lange Louis G's Form 4 filing
NewAmsterdam Pharma Co N.V. (NAMS) · filed Mar 12, 2026
- Accession no.
- 0001193125-26-104239
- Filed
- Mar 12, 2026
- Trade date
- Mar 11, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.36M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lange Louis GCIK 0001238401 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | Ordinary Shares | SSaleDisposed | −44,173 | $30.41 | −$1,343,300.93 | 10,806 | Direct | |
| Mar 11, 2026 | Ordinary Shares | SSaleDisposed | −446 | $31.23 | −$13,928.58 | 10,360 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.